Your search returned 5 results.

Results
	1.	Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors: Swain, Sandra M PMID: 36944848 Year: 2023 Citation: Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun. Department: Associate Dean for Research Development MedStar Health Medline publication type: Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G DOI: https://dx.doi.org/10.1007/s10549-023-06881-8 Add to cart (remove)
	2.	Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records. MedStar authors: Swain, Sandra M PMID: 37167571 Year: 2023 Citation: JCO Oncology Practice. 19(7):435-445, 2023 07. Institution: Associate Dean for Research Development MedStar Health Medline publication type: Journal Article Form of publication: Journal Article All authors: Dang CT, Du Toit Y, Hurvitz SA, Knott A, Polito L, Restuccia E, Sanglier T, Shim J, Swain SM DOI: https://dx.doi.org/10.1200/OP.22.00565 Add to cart (remove)
	3.	Breast Cancer and Heart Failure. [Review] MedStar authors: Barac, Ana PMID: 30449381 Year: 2019 Citation: Heart Failure Clinics. 15(1):65-75, 2019 Jan. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Almuwaqqat Z, Barac A, Meisel JL, Parashar S DOI: https://dx.doi.org/10.1016/j.hfc.2018.08.007 Add to cart (remove)
	4.	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. MedStar authors: Swain, Sandra M PMID: 27812689 Year: 2017 Citation: JAMA Oncology. 3(3):335-341, 2017 Mar 01 Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Bandos H, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Johnson NL, Kim SR, Lipchik C, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N DOI: https://dx.doi.org/10.1001/jamaoncol.2016.4884 Add to cart (remove)
	5.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)

Powered by Koha